Jun 3, 2019

DaHui Advises Anji Pharmaceuticals on Acquisition of Late-Stage Clinical Asset

Anji Pharmaceuticals, Inc. announced the acquisition of global development rights for a novel delayed-release formulation of metformin (Metformin DR) from Elcelyx Therapeutics. Metformin DR is an investigational product designed to target metformin delivery to the lower small intestine for the treatment of diabetes.

Based in the global pharmaceutical hubs of Cambridge, MA and Shanghai, China, Anji Pharmaceuticals is focused on tackling high-value pharmaceutical targets validated by human genetics. DaHui represented Anji Pharmaceuticals as its sole legal counsel on this acquisition, with the team being led by partner Zheng Zha and counsel Mark Young.


Subscribe to our newsletter.

Related Services

Healthcare & Life Sciences
Mergers & Acquisitions

Related Lawyers

Related News

Jan 20, 2023

DaHui Contributes as Thought Leader in Chambers’ Expert Focus
Read Article

Jan 7, 2023

DaHui Adds Yet Another Partner, Yun Chen, to IP and DR Practices
Read Article

Dec 20, 2022

DaHui Grows International Trade and DR Practices with Lateral Partner Joining of Yi Dai
Read Article

© DaHui Lawyers